Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced the completion of enrollment in its nationwide, multicenter MOTION Study of its mild® Procedure. The novel prospective, randomized controlled study will collect clinically validated, patient-reported pain and function outcome measures, as well as real world quality of life data using Fitbit activity trackers. The study enrolled approximately 150 patients who were 50-80 years of age from 19 sites across the United States and patients will be followed for two years. It is the second large, multi-center study, randomized controlled trial that has been done on the mild Procedure.

The mild Procedure is a clinically proven outpatient LSS treatment that removes the cause of stenosis through a portal the size of a baby aspirin. It requires no implants, no general anesthesia, no stitches, and no overnight hospital stay.

“We are pleased that we were able to reach full enrollment so quickly and look forward to seeing the six-month results next year,” said Dr. Tim Deer, an interventional pain specialist, president and CEO of The Spine and Nerve Center of the Virginias and national principal investigator for the MOTION Study. “This study will provide high quality data using validated pain and function outcomes measures, but we are most excited about the Fitbit activity data. This data is critical to demonstrating the real-world quality of life improvements patients experience with the mild Procedure,” added Dr. Deer.

The mild Procedure has been performed on more than 25,000 patients and its safety and efficacy have been analyzed in more than 13 clinical studies and 20 publications. Study data has shown clinically meaningful and statistically significant mobility improvement and pain reduction, with no serious procedure complications in any clinical trial.

“Vertos believes that it is critical for clinicians and patients to have access to high quality data in order to make good clinical decisions, so we are excited that enrollment is complete for the MOTION study,” said Eric Wichems, president and CEO of Vertos Medical. “We want to thank all the physicians in our study that have actively enrolled patients.”

For more information about Vertos Medical, please visit www.vertosmed.com.

Vertos Medical Inc. is a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS). Its proprietary technologies include the mild® instrumentation kit, which enables a safe, outpatient, minimally invasive, fluoroscopically guided therapeutic LSS treatment that requires no general anesthesia, no implants, and no stitches. LSS is primarily a degenerative, age-related narrowing of the lower spinal canal that causes symptoms of pain and numbness in the lower back, legs, or buttocks. The mild Procedure treats this condition by restoring space in the spinal canal using specialized mild devices to remove hypertrophic ligamentum flavum through a 5.1-mm treatment portal. Clinical studies show that the mild procedure can help LSS patients stand longer and walk farther with less pain.1 No major device-related complications have been reported in any clinical trial.2 Vertos Medical headquarters is located in Aliso Viejo, CA. To learn more about how the mild Procedure treats LSS, go to www.vertosmed.com/products/.

Latest news

Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024

Full release here: Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps

GT Medical Technologies Names Per Langoe As CEO
February 20, 2024

Full release here: GT Medical Technologies, Inc. Names Per Langoe As CEO

MVM invests in icotec
January 24, 2024

ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PR Newswire/ — icotec ag, the leading company in the field of innovative spinal […]

MVM invests in Gynesonics
November 1, 2023

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Gynesonics® Inc., a women’s healthcare company focused on the development of […]

SkyCell Featured in TechCrunch
October 31, 2023

Full release here: SkyCell raises $57M at a $600M valuation to build smart containers for pharmaceutical transport | TechCrunch

MVM invests in BioProtect
September 27, 2023

TZUR IGAL, Israel, Sept. 27, 2023 /PRNewswire/ — BioProtect Ltd, a private Med Tech company focused on providing innovative, biodegradable spacing solutions, announced today the […]

VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023

SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]

MVM invests in CurvaFix
July 14, 2023

BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]

Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023

ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]